Differences in characteristics and risk of cardiovascular disease in familial hypercholesterolemia patients with and without tendon xanthomas: A systematic review and meta-analysis

Atherosclerosis

Volumn 207, Issue 2, 2009, Pages 311-317

  Oosterveer, Daniëlla M ^a   Versmissen, Jorie ^a   Yazdanpanah, Mojgan ^a   Hamza, Taye H ^a   Sijbrands, Eric J G ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Cardiovascular disease; Familial hypercholesterolemia; Systematic review; Xanthomas

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; TRIACYLGLYCEROL;

AGE DISTRIBUTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; FAMILIAL HYPERCHOLESTEROLEMIA; GENE MUTATION; HETEROZYGOSITY; HUMAN; LITERATURE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SEX DIFFERENCE; SYSTEMATIC REVIEW; TENDON XANTHOMA; XANTHOMA;

ADOLESCENT; ADULT; AGE FACTORS; AGED; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHILD; CHOLESTEROL, LDL; FEMALE; GENETIC TESTING; HETEROZYGOTE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; MALE; MIDDLE AGED; MUSCULOSKELETAL DISEASES; MUTATION; RECEPTORS, LDL; RISK ASSESSMENT; RISK FACTORS; SEX FACTORS; TENDONS; TRIGLYCERIDES; XANTHOMATOSIS; YOUNG ADULT;

EID: 70450285407     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.04.009     Document Type: Review

References (46)

1. Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management, Scientific Steering Committee on behalf of the Simon Broome Register Group. Atherosclerosis 142 (1999) 105-112
2. Williams R.R., Hunt S.C., Schumacher M.C., et al. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am J Cardiol 72 (1993) 171-176
3. Civeira F., Castillo S., Alonso R., et al. Tendon xanthomas in familial hypercholesterolemia are associated with cardiovascular risk independently of the low-density lipoprotein receptor gene mutation. Arterioscler Thromb Vasc Biol 25 (2005) 1960-1965
4. van Aalst-Cohen E.S., Jansen A.C., Tanck M.W., et al. Diagnosing familial hypercholesterolaemia: the relevance of genetic testing. Eur Heart J 27 (2006) 2240-2246
5. Neil H.A., Huxley R.R., Hawkins M.M., Durrington P.N., Betteridge D.J., and Humphries S.E. Comparison of the risk of fatal coronary heart disease in treated xanthomatous and non-xanthomatous heterozygous familial hypercholesterolaemia: a prospective registry study. Atherosclerosis 170 (2003) 73-78
6. Humphries S.E., Cranston T., Allen M., et al. Mutational analysis in UK patients with a clinical diagnosis of familial hypercholesterolaemia: relationship with plasma lipid traits, heart disease risk and utility in relative tracing. J Mol Med (Berlin Germany) 84 (2006) 203-214
7. DerSimonian R., and Laird N. Meta-analysis in clinical trials. Control Clin Trials 7 (1986) 177-188
8. Beaumont V., Jacotot B., and Beaumont J.L. Ischaemic disease in men and women with familial hypercholesterolaemia and xanthomatosis. A comparative study of genetic and environmental factors in 274 heterozygous cases. Atherosclerosis 24 (1976) 441-450
9. Andersen G.E., and Clausen J. Tracing and treatment of children with essential familial hypercholesterolemia. Z Ernahrungswiss 11 (1972) 120-137
10. Schrott H.G., Goldstein J.L., Hazzard W.R., McGoodwin M.M., and Motulsky A.G. Familial hypercholesterolemia in a large kindred. Evidence for a monogenic mechanism. Ann Intern Med 76 (1972) 711-720
11. Miettinen T.A., and Aroyuj A. Comparison of clinical findings in patients with hyperglyceridaemia and familial hypercholesterolaemia. Ann Clin Res 5 (1973) 1-6
12. Streja D., Steiner G., and Kwiterovich Jr. P.O. Plasma high-density lipoproteins and ischemic heart disease: studies in a large kindred with familial hypercholesterolemia. Ann Intern Med 89 (1978) 871-880
13. Gagne C., Moorjani S., Brun D., Toussaint M., and Lupien P.J. Heterozygous familial hypercholesterolemia. Relationship between plasma lipids, lipoproteins, clinical manifestations and ischaemic heart disease in men and women. Atherosclerosis 34 (1979) 13-24
14. Garces C., Rodriguez Artalejo F., Serrano A., et al. Clinical manifestations of heterozygote familial hypercholesterolemia in Spain. Study of 301 cases from the central and northern areas. Med Clin 114 (2000) 50-51
15. Heath K.E., Gudnason V., Humphries S.E., and Seed M. The type of mutation in the low density lipoprotein receptor gene influences the cholesterol-lowering response of the HMG-CoA reductase inhibitor simvastatin in patients with heterozygous familial hypercholesterolaemia. Atherosclerosis 143 (1999) 41-54
16. Bartolotta T.V., Taibbi A., Malizia G., et al. Real-time spatial compound sonography of Achilles tendon in patients with heterozygous familial hypercholesterolaemia and normal physical examination. Radiol Med 112 (2007) 562-571
17. Yamakawa K., Yanagi H., Saku K., et al. Family studies of the LDL receptor gene of relatively severe hereditary hypercholesterolemia associated with Achilles tendon xanthomas. Hum Genet 86 (1991) 445-449
18. Tsouli S.G., Kiortsis D.N., Lourida E.S., et al. Autoantibody titers against OxLDL are correlated with Achilles tendon thickness in patients with familial hypercholesterolemia. J Lipid Res 47 (2006) 2208-2214
19. Aji W., Ravalli S., Szabolcs M., et al. l-Arginine prevents xanthoma development and inhibits atherosclerosis in LDL receptor knockout mice. Circulation 95 (1997) 430-437
20. Watanabe Y., Ito T., Shiomi M., et al. Preventive effect of pravastatin sodium, a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on coronary atherosclerosis and xanthoma in WHHL rabbits. Biochim Biophys Acta 960 (1988) 294-302
21. Yamamoto A., Hara H., Takaichi S., Wakasugi J., and Tomikawa M. Effect of probucol on macrophages, leading to regression of xanthomas and atheromatous vascular lesions. Am J Cardiol 62 (1988) 31B-36B
22. Artieda M., Cenarro A., Junquera C., et al. Tendon xanthomas in familial hypercholesterolemia are associated with a differential inflammatory response of macrophages to oxidized LDL. FEBS Lett 579 (2005) 4503-4512
23. Mabuchi H., Ito S., Haba T., Ueda K., and Ueda R. Discrimination of familial hypercholesterolemia and secondary hypercholesterolemia by Achilles' tendon thickness. Atherosclerosis 28 (1977) 61-68
24. Murano S., Shinomiya M., Shirai K., Saito Y., and Yoshida S. Characteristic features of long-living patients with familial hypercholesterolemia in Japan. J Am Geriatr Soc 41 (1993) 253-257
25. Steinmetz A., Schmitt W., Schuler P., Kleinsorge F., Schneider J., and Kaffarnik H. Ultrasonography of achilles tendons in primary hypercholesterolemia. Comparison with computed tomography. Atherosclerosis 74 (1988) 231-239
26. Lehtonen A., Makela P., Viikari J., and Virtama P. Achilles tendon thickness in hypercholesterolaemia. Ann Clin Res 13 (1981) 39-44
27. Lugo-Somolinos A., and Sanchez J.E. Xanthomas: a marker for hyperlipidemias. Bol Asoc Med P R 95 (2003) 12-16
28. Junyent M., Gilabert R., Zambon D., et al. The use of Achilles tendon sonography to distinguish familial hypercholesterolemia from other genetic dyslipidemias. Arterioscler Thromb Vasc Biol 25 (2005) 2203-2208
29. Mabuchi H., Tatami R., Haba T., et al. Achilles tendon thickness and ischemic heart disease in familial hypercholesterolemia. Metabolism 27 (1978) 1672-1679
30. Kiortsis D.N., Argyropoulou M.I., Xydis V., Tsouli S.G., and Elisaf M.S. Correlation of Achilles tendon thickness evaluated by ultrasonography with carotid intima-media thickness in patients with familial hypercholesterolemia. Atherosclerosis 186 (2006) 228-229
31. Abadie E., Masquet C., Guiomard A., and Passa P. Coronary insufficiency in hypercholesterolemic xanthomatosis. Angiographic aspects. Presse Med 12 (1983) 335-338
32. Ferrieres J., Lambert J., Lussier-Cacan S., and Davignon J. Coronary artery disease in heterozygous familial hypercholesterolemia patients with the same LDL receptor gene mutation. Circulation 92 (1995) 290-295
33. Tonstad S., Joakimsen O., Stensland-Bugge E., Ose L., Bonaa K.H., and Leren T.P. Carotid intima-media thickness and plaque in patients with familial hypercholesterolaemia mutations and control subjects. Eur J Clin Invest 28 (1998) 971-979
34. Bertolini S., Cantafora A., Averna M., et al. Clinical expression of familial hypercholesterolemia in clusters of mutations of the LDL receptor gene that cause a receptor-defective or receptor-negative phenotype. Arterioscler Thromb Vasc Biol 20 (2000) E41-52
35. Carmena R., Roy M., Roederer G., Minnich A., and Davignon J. Coexisting dysbetalipoproteinemia and familial hypercholesterolemia. Clinical and laboratory observations. Atherosclerosis 148 (2000) 113-124
36. Descamps O.S., Leysen X., Van Leuven F., and Heller F.R. The use of Achilles tendon ultrasonography for the diagnosis of familial hypercholesterolemia. Atherosclerosis 157 (2001) 514-518
37. Dedoussis G.V., Skoumas J., Pitsavos C., et al. FH clinical phenotype in Greek patients with LDL-R defective vs. negative mutations. Eur J Clin Invest 34 (2004) 402-409
38. Ejarque I., Real J.T., Chaves F.J., et al. Clinical and biochemical characteristics of familial ligand-defective apo B-100 in a South European population. Med Clin 123 (2004) 456-459
39. Firth J.C., and Marais A.D. Familial hypercholesterolemia: the Cape Town experience. S Afr Med J 98 (2008) 99-104
40. Oosterveer DM, Versmissen J, Yazdanpanah M, van der Net JB, Defesche JC, Kastelein JJP, Sijbrands EJG. 5-Lipoxygenase activating protein (ALOX5AP) gene variants associate with the presence of xanthomas in familial hypercholesterolemia. Atherosclerosis, 2009, doi:10.1016/j.atherosclerosis.2009.02.019.
41. van der Net J.B., Versmissen J., Oosterveer D.M., et al. Arachidonate 5-lipoxygenase-activating protein (ALOX5AP) gene and coronary heart disease risk in familial hypercholesterolemia. Atherosclerosis 203 (2009) 472-478
42. Wittekoek M.E., Moll E., Pimstone S.N., et al. A frequent mutation in the lipoprotein lipase gene (D9N) deteriorates the biochemical and clinical phenotype of familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 19 (1999) 2708-2713
43. Sundaram S.S., Bove K.E., Lovell M.A., and Sokol R.J. Mechanisms of disease: inborn errors of bile acid synthesis. Nat Clin Pract Gastroenterol Hepatol 5 (2008) 456-468
44. Jansen A.C., van Aalst-Cohen E.S., Tanck M.W., et al. Genetic determinants of cardiovascular disease risk in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 25 (2005) 1475-1481
45. de Sauvage Nolting P.R.W., Defesche J., Buirma R.J.A., Hutten B.A., Lansberg P.J., and Kastelein J.J.P. Prevalence and significance of cardiovascular risk factors in a large cohort of patients with familial hypercholesterolemia. J Intern Med 253 (2003) 161-168
46. Thompson S.G., and Higgins P.T. How should meta-regression analyses be undertaken and interpreted?. Stat Med 21 (2002) 1559-1573